Idiopathic Pulmonary Fibrosis Market Expected To Enable the Stakeholders for Market Opportunities

According to a new report published by Allied Market Research, Idiopathic Pulmonary Fibrosis Market by Drug Type: Global Opportunity Analysis and Industry Forecast, 20172023, the global idiopathic pulmonary fibrosis market was valued at $1,616 million in 2016 and is expected to reach. It grew to $3,569 million by 2023, with a CAGR of 11.9% from 2017 to 2023. Peri penny money accounted for more than half of the total market in 2016.

Click Here to Access Free Sample Report: https://www.alliedmarketresearch.com/request-sample/4407

Idiopathic pulmonary fibrosis is a disease in which lung tissue becomes thick and stiff over time, resulting in a decrease in the tissue's ability to carry oxygen. An increase in the elderly population and an increase in patients suffering from idiopathic pulmonary fibrosis are expected to drive the market growth. In addition, an increase in the smoking population promotes market growth. However, market growth is limited because no treatment options are available to fully cure the disease.

know more:https://www.alliedmarketresearch.com/idiopathic-pulmonary-fibrosis-market

Perifenidone is expected to dominate the market during the analysis period as this drug helps slow scarring and preserve lung function. Nintedanib is expected to record the highest CAGR of 12.2% over the forecast period.

Key Results of the Idiopathic Pulmonary Fibrosis Market:
• Nintedanib is expected to grow at a CAGR of 12.2% over the forecast period.
• Pirpenidone accounted for more than half of the global idiopathic pulmonary fibrosis market in 2016.
• France and Germany jointly occupied more than a third of the European idiopathic pulmonary fibrosis market in 2016.
• Japan was the largest shareholder, accounting for more than a third of the Asia Pacific idiopathic pulmonary fibrosis market in 2016.
• Brazil is the majority shareholder in the LAMEA idiopathic pulmonary fibrosis market in 2016.

Purchase Inquiry: https://www.alliedmarketresearch.com/purchase-enquiry/4407

The Asia Pacific region is expected to record the highest CAGR of 13.0% over the forecast period due to a growing population suffering from fibrotic disease and a growing aging population. In addition, the increase in medical expenditure provides a favorable opportunity for market growth.

The major companies featured in the report include MediciNova, Inc., Boehringer Ingelheim, F. Hoffmann-La Roche, FibroGen, Inc., Promedior, Inc., Merck & Co., Inc., Galapagos NV, Biogen, Bristol-Myers Squibb Company, Prometic Life Sciences Inc. And Cipla Inc.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web:https://www.alliedmarketresearch.com
Follow Us on LinkedIn:https://www.linkedin.com/company/allied-market-research

About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.